2023 Updates in Clinical Oncology – Gastrointestinal and Recent Advances in Pediatric Neuro-oncology скачать в хорошем качестве

2023 Updates in Clinical Oncology – Gastrointestinal and Recent Advances in Pediatric Neuro-oncology

Enduring Activity: 2023 Updates in Clinical Oncology – Program 5: Gastrointestinal and Recent Advances in Pediatric Neuro-oncology Evaluation and Credit: https://www.surveymonkey.com/r/2023UC... Target Audience This activity is targeted toward physicians, physicians assistants, nurse practitioners,pharmacists, nurses and other health care providers in the practice specialties of family medicine, gynecology, obstetrics/gynecology, oncology (and subspecialties), pediatrics, pathology, preventive medicine, radiology and surgery. Statement of Need This symposium has been designed to meet the educational needs of health care providers by presenting advancement and guidelines for improved patient care in clinical oncology. This program will address all primary areas of clinical oncology. Providers in the field have compiled the most salient practice-shifting information from abstracts and podium presentations, including surgical, medical, diagnostic, preventive and therapeutic clinical knowledge. Objectives 1) Identify state-of-the-art treatment protocols for oncology patients. 2) Discuss new strategies for the prevention and diagnosis of cancer. 3) Describe standard therapeutic practices and the application of the newest therapies in the treatment of cancer patients. Program 5 - Presentations and Faculty “Gastrointestinal (Non-colorectal) Cancers” Jaspreet S. Grewal, M.D. “Gastrointestinal (Colorectal) Cancers” Michael F. Driscoll, M.D. “Recent Advances in Pediatric Neuro-oncology” Mustafa Barbour, M.D. Faculty Disclosure Michael F. Driscoll, M.D. and Mustafa Barbour, M.D. have no relevant financial conflicts of interest to disclose. Jaspreet S. Grewal, M.D. disclosures a financial relationship with BMS, Ipsen and Eli Lily (Speaker Bureaus). Planner Disclosure The planners of this activity have no relevant conflicts of interest to disclose. The planners for this activity include the course director, Don A. Stevens, M.D.; and the planning committee members, Karen Busse, M.S., CCMEC; Pamela Jacobs, MHA, BSN, RN., CRNI, OCN; Joseph J. Maly, M.D.; Sandra Stroud, B.A., CCMEC; Sally Sturgeon, DNP, R.N., SANE-A, AFN-BC; and Lauren White, CAP-OM Physician Credits Accreditation This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education Designation Norton Healthcare designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For information related to CME, contact the Norton Healthcare Center for Continuing Medical, Provider & Nursing Education at (502) 446-5955 or [email protected] . Nursing Credits Norton Healthcare Institute for Education & Development is approved with distinction as a provider of nursing continuing professional development by the South Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. This continuing professional development activity has been approved for 1.25 contact hours. In order for nursing participants to obtain credits, they must claim attendance by attesting to the number of hours in attendance. For more information related to nursing credits, contact Sally Sturgeon, DNP, R.N., SANE-A, AFN-BC, (502) 446-5889 or [email protected] . Date of Original Release | November 2023 Course Termination Date | November 2025 Contact Information | Center for Continuing Provider, Medical and Nursing Education [email protected] References 1. SEER 22 Incidence & U.S. Mortality 2016–2020, Ages 0–19. Rates are Age-Adjusted 2. McNeill K. A. (2016). Epidemiology of Brain Tumors. Neurologic clinics, 34(4), 981–998. 3. Gnekow AK et al. Neuro-Oncology 14(10):1265–1284, 2012 4. Fangusaro et al. Lancet Oncol 2019; 20: 1011–22 5. Gajjar A et al. J Clin Oncol (2015) 33:2986-2998 6. Packer, R. J. et al. J Clin Oncol; 24:4202-4208 2006 7. Reddy, A. T et al. (2020). Journal of clinical oncology, 38(11), 1175–1185